logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

CDK4/6 inhibitors show broad benefit in HR+/HER2- metastatic breast cancer

Pooled analysis of 4200 patients in 7 clinical trials of 3 CDK4/6 inhibitors approved by FDA and EMA.